阿杜卡努马布抗粉样蛋白免疫疗法诱导持续的微质和免疫变化
Mika P Cadiz1,2, Katelin A Gibson1, Kennedi T Todd1
1Department of Neuroscience, Mayo Clinic, Scottsdale, AZ, USA.
The Journal of experimental medicine
|January 16, 2024
概括
在阿尔茨海默氏症模型中,阿杜卡努马布治疗可以清除粉样质斑块,但退出导致斑块再生. 微质在清除中起着关键作用,但在停止治疗后失去这一功能,影响长期疗效.
科学领域:
- 神经科学是一个神经科学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 阿尔茨海默病 (AD) 的特点是粉样β (Aβ) 斑块.
- 阿杜卡努马布是一种针对AD的抗粉样蛋白免疫疗法.
- 阿杜卡努马布的斑块清除机制和长期影响尚不清楚.
研究的目的:
- 调查阿杜卡努马布对Aβ,神经性缩,星球细胞和微质细胞的影响.
- 在APP/PS1小鼠模型中评估阿杜卡努马布治疗和停药的影响.
- 阐明微质在阿杜卡努马布介导的Aβ清除和长期结果中的作用.
主要方法:
- 使用了APP/PS1粉样蛋白小鼠模型.
- 服用阿杜卡努马布治疗和停药后监测的效果.
- 分析了Aβ水平,神经质,星细胞和微质激活,以及微质的转录基因特征.
主要成果:
- 阿杜卡努马布治疗减少了与微质和星球细胞激活相关的粉样蛋白和神经质变.
- 在治疗过程中,微细胞表现出对斑块的招募,并采用了亲细胞的签名.
- 停药后Aβ降低持续了15周,但没有持续30周,与微质特征损失和斑块再积累相吻合.
结论:
- 微质细胞对于阿杜卡努马布的Aβ清除至关重要,在治疗过程中采用特定的特征.
- 停药后斑块的重新积累表明,微质细胞在没有持续治疗的情况下无法抑制它.
- 进一步研究免疫疗法戒断对于评估阿尔茨海默病的长期安全性和疗效至关重要.
更多相关视频
10:19Neurodegeneration in an Animal Model of Chronic Amyloid-beta Oligomer Infusion Is Counteracted by Antibody Treatment Infused with Osmotic Pumps
Published on: August 14, 2016
9.3K
09:33Quantitative 3D In Silico Modeling q3DISM of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
8.0K
相关概念视频
01:22Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
166
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
166